CSIMarket
 


Genocea Biosciences Inc   (GNCA)
Other Ticker:  
 

Cumulative Genocea Biosciences Inc 's Quick Ratio for Trailing Twelve Months Period

GNCA's Quick Ratio for Trailing Twelve Months Period and Cash & cash equivalent, Current Liabilities growth


Select the Comparisons : Select the Ratio:

GNCA Quick Ratio for Trailing Twelve Months Period

(Mar 31 2022)
I. Quarter
(Dec 31 2021)
IV. Quarter
(Sep 30 2021)
III. Quarter
(Jun 30 2021)
II. Quarter
(Mar 31 2021)
I. Quarter
Y / Y Current Liabilities Growth 57.83 % -25.25 % -38.26 % -31.09 % -22.1 %
Y / Y Cash & cash equivalent Growth -69.51 % -53.43 % -44.18 % 173.2 % 149.1 %
Quick Ratio for Trailing Twelve Months Period 2.51 3.56 3.87 3.91 3.13
Total Ranking # 1482 # 1176 # 894 # 859 # 998
Seq. Current Liabilities Growth -3.5 % 27.06 % -0.86 % 29.83 % -54.29 %
Seq. Cash & cash equivalent Growth -45.79 % -24.05 % -19.03 % -8.53 % -17.22 %


Quick Ratio for Trailing Twelve Months Period Comment for 12 Months ending at Mar 31 2022
On the trailing twelve months basis Due to decrease in Current Liabilities in the I. Quarter to $18 millions, average cumulative Quick Ratio for Trailing Twelve Months Period decreased to 2.51 below Genocea Biosciences Inc average Quick Ratio for Trailing Twelve Months Period.
Quick Ratio for Trailing Twelve Months Period is the average cumulative value over the last four quarters.

Among companies operatig within Biotechnology & Pharmaceuticals industry 168 other companies have achieved higher Quick Ratio for Trailing Twelve Months Period than Genocea Biosciences Inc . While overall ranking remained unchanged compare to previous quarter at no. .

What is Quick Ratio?
Learn more about GNCA
Quick Ratio GNCA in the most recent quarter
Quick Ratio for Trailing Twelve Months Period Company Ranking
Within: No.
Industry # 169
Sector # 923
S&P 500 # 2367


Quick Ratio for Trailing Twelve Months Period Statistics
High Average Low
13.29 4.22 2.22
(Dec 31 2016)   (Dec 31 2017)




Companies with similar average Quick Ratio for Trailing Twelve Months Period for 12 months ending Mar 31 2022, within Biotechnology & Pharmaceuticals Industry Quick Ratio for Trailing Twelve Months Period
Compugen Ltd  6.91 
Cognition Therapeutics inc   6.85 
X4 Pharmaceuticals Inc  6.79 
Inhibrx Inc   6.78 
Biocardia Inc  6.65 
Halozyme Therapeutics Inc   6.65 
Sophia Genetics Sa  6.57 
Adaptimmune Therapeutics Plc  6.34 
Gritstone Bio Inc   6.34 
Jasper Therapeutics Inc   6.28 
Biomx Inc   6.26 
Poseida Therapeutics Inc   6.10 
Cardiol Therapeutics inc   6.07 
Sutro Biopharma Inc   6.00 
Sqz Biotechnologies Company  5.93 
Codiak Biosciences Inc   5.79 
Kaleido Biosciences Inc   5.74 
Aligos Therapeutics Inc   5.74 
Orchard Therapeutics Plc  5.51 
Denali Therapeutics Inc   5.51 
Alector Inc   5.43 
Evaxion Biotech A  5.42 
Kiromic Biopharma Inc   5.40 
Pluri Inc   5.25 
Windtree Therapeutics Inc  5.23 
Armata Pharmaceuticals Inc   5.12 
Palisade Bio Inc   5.11 
Exelixis Inc   5.08 
Axcella Health Inc   4.92 
Seagen Inc   4.73 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com